Ultragenyx Pharmaceutical
RARE • NASDAQ
Ultragenyx Pharmaceutical is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Emil D. Kakkis, with a market cap of $2.2B.
CEOEmil D. Kakkis
Next Earnings
Upcoming earnings announcement for Ultragenyx Pharmaceutical
Date
Tuesday, May 5, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.44
Revenue Estimate
$165.8M
Earnings History
Past 12 earnings reports for Ultragenyx Pharmaceutical
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Q4 2025 | -$1.29Est: -$1.18 | -9.3% | $207.0MEst: $202.3M | +2.3% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$1.81Est: -$1.22 | -48.4% | $159.9MEst: $167.1M | -4.3% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$1.17Est: -$1.30 | +10.0% | $166.5MEst: $161.5M | +3.1% | 10-Q |
| May 6, 2025 | Q1 2025 | -$1.57Est: -$1.64 | +4.3% | $139.3MEst: $144.5M | -3.6% | 10-Q |
| Feb 13, 2025 | Q4 2024 | -$1.39Est: -$1.27 | -9.4% | $164.9MEst: $158.7M | +3.9% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$1.40Est: -$1.45 | +3.4% | $139.5MEst: $135.8M | +2.7% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$1.52Est: -$1.72 | +11.6% | $147.0MEst: $123.2M | +19.4% | 10-Q |
| May 2, 2024 | Q1 2024 | -$2.03Est: -$1.76 | -15.3% | $108.8MEst: $116.2M | -6.3% | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$1.52Est: -$1.62 | +6.2% | $127.4MEst: $119.4M | +6.7% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$2.23Est: -$2.06 | -8.3% | $98.1MEst: $110.0M | -10.9% | — |
| Aug 3, 2023 | Q2 2023 | -$2.25Est: -$2.11 | -6.6% | $108.3MEst: $105.2M | +3.0% | 10-Q |
| May 4, 2023 | Q1 2023 | -$2.33Est: -$1.98 | -17.7% | $100.5MEst: $104.7M | -4.0% | — |